Must be used in combination with PEG-interferon and ribavirin (see separate entries)

Combination treatment is contra-indicated in pregnant women and men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin, or in coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, or with potent CYP3A4/5 inducers.

Our database has 21 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top